Stop Use of Ivermectin for COVID-19: AMA, Pharmacist Groups
THURSDAY, Sept. 2, 2021 (HealthDay News) -- The prescribing, dispensing, and use of ivermectin to prevent or treat COVID-19 outside of clinical trials must end immediately, the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists say.
The drug has U.S. Food and Drug Administration approval to treat people with infections caused by internal and external parasites but is not approved to prevent or treat COVID-19. Ivermectin is also available for veterinary use in horses and other animals, but medications intended for animals should not be used by humans.
"We are alarmed by reports that outpatient prescribing for and dispensing of ivermectin have increased 24-fold since before the pandemic and increased exponentially over the past few months," the groups said in a statement. They noted that calls to poison control centers related to ivermectin have increased fivefold compared with before the pandemic.
No form of ivermectin has been approved to treat or prevent COVID-19, the FDA emphasized. It said it was compelled to issue a warning due to "a lot of misinformation" around the drug, according to the update.
The U.S. Centers for Disease Control and Prevention also issued an advisory saying ivermectin is not authorized or approved for the prevention or treatment of COVID-19. The CDC has warned about the potentially toxic effects of the drug, including "nausea, vomiting and diarrhea. Overdoses are associated with hypotension and neurologic effects such as decreased consciousness, confusion, hallucinations, seizures, coma, and death."
Related Posts
Un peligroso virus encontrado en los monos podría saltar a los humanos
MARTES, 4 de octubre de 2022 (HealthDay News) -- La comunidad global de salud...
Lograr que los niños vayan a la escuela a pie y en bicicleta conduce a una buena aptitud física a largo plazo
VIERNES, 9 de septiembre de 2022 (HealthDay News) -- Los niños que van a la...
J&J to Pay More Than $300 Million in Pelvic Mesh Case
WEDNESDAY, April 13, 2022 (HealthDay News) -- Johnson & Johnson must pay...
Mediterranean, Low-Fat Dietary Programs Beneficial for Elevated Cardiovascular Risk
FRIDAY, March 31, 2023 (HealthDay News) -- Mediterranean and low-fat dietary...